The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel...

Area of Science:

• Cardiovascular Medicine
• Clinical Pharmacology
• Biochemistry

Background:

• Metabolic abnormalities are linked to coronary artery disease (CAD) severity and prognosis.
• Certain metabolic factors can impair the effectiveness of antiplatelet drugs like clopidogrel.
• Elevated free fatty acids (FFAs) are common in CAD patients and indicate metabolic dysfunction.

Purpose of the Study:

• To investigate if elevated FFAs contribute to residual platelet reactivity in CAD patients treated with clopidogrel.
• To explore the association between FFAs and adenosine diphosphate (ADP)-induced platelet aggregation under clopidogrel therapy.

Main Methods:

• Logistic regression analysis was used to assess the association between FFAs levels and high residual platelet reactivity (HRPR).
• The study included 1,277 CAD patients undergoing clopidogrel treatment.
• HRPR was defined by specific thresholds for ADP-induced platelet inhibition rate and maximum amplitude.

Main Results:

• 38.1% of patients exhibited HRPR.
• Patients with higher FFAs levels (>0.445 mmol/L) had a significantly greater proportion of HRPR (46.4%) compared to those with lower levels (32.6%).
• Higher FFAs were independently associated with HRPR (adjusted OR = 1.745).

Conclusions:

• Elevated FFAs levels are independently associated with high residual platelet reactivity in CAD patients on clopidogrel.
• Increased FFAs may enhance residual platelet reactivity induced by ADP, potentially impacting clopidogrel's antiplatelet efficacy.
• These findings highlight FFAs as a potential factor influencing clopidogrel response in CAD.